- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01064986
The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers
May 20, 2014 updated by: Rutgers, The State University of New Jersey
Corticosteroids are substances produced by the adrenal gland to help the body fight against infection or injury.
Hydrocortisone is a man-made form of this substance.
Endotoxin is a man-made substance, which causes the body to "mimic" sickness(fever,chills,and achiness)for a few hours.
This study is designed to give hydrocortisone before and after Endotoxin to determine if this medication can prevent or relieve any of the symptoms caused by the Endotoxin.
Study Overview
Status
Completed
Conditions
Detailed Description
The body's immune response to injury otr infection is very complex.
Immune cell activity, the release of specific mediators (such as proteins), genetics (Deoxyribonucleic acid or DNA) and/or the body's "instructions" for making proteins (Ribonucleic Acid or RNA) may effect the body's clinical response to a stress such as an infection.Hydrocortisone is a substance produced by the body (in the adrenal gland)in response to stress such as infection or injury.
Endotoxin is a man- made substance, which causes the body to "mimic" sickness (fever, chills, and achiness) for a few hours.
This study is designed to give hydrocortisone before and/or after endotoxin to determine if this medication can prevent or relieve any of the symptoms caused by endotoxin.In addition, this study may determine whether any of the above(proteins,DNA,RNA,etc.)
correlate with or affect the body's response to hydrocortisone and/or endotoxin.
This will enable the investigator to better understand whether treatment with this substance can alter the body's immune response.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Rutgers-Rwjms
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- General good health as demonstrated by medical history, physical& laboratory tests
- Age between 18 and 40 years
- Written informed consent prior to the performance of any study related procedures
Exclusion Criteria:
- History of cancer, rheumatoid arthritis, or immunological, renal, hepatic, endocrine, neurologic, heart disease or hypertension
- Any medication taken in past 48 hrs (except birth control)
- Recent history of alcohol or drug abuse
- Unable to provide written informed consent
- Exposure to any experimental agent or procedure within 30 days of study
- Pregnant or breast-feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: A
IV Endotoxin plus saline vehicle (placebo)
|
Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
Other Names:
Saline vehicle (placebo)
|
|
Active Comparator: B
IV Endotoxin plus IV hydrocortisone
|
Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
Other Names:
Hydrocortisone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Physiological, Hematological, Immunological Responses
Time Frame: 0.5-24 hrs post Endotoxin administration
|
0.5-24 hrs post Endotoxin administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
February 5, 2010
First Submitted That Met QC Criteria
February 8, 2010
First Posted (Estimate)
February 9, 2010
Study Record Updates
Last Update Posted (Estimate)
May 22, 2014
Last Update Submitted That Met QC Criteria
May 20, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Bacteremia
- Toxemia
- Endotoxemia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Epinephrine
- Hydrocortisone
- Hydrocortisone hemisuccinate
Other Study ID Numbers
- 0220070126
- NIH/DHHS (Other Grant/Funding Number: GM34695)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
Han TongyanCompletedLower Respiratory Tract Infections | RSV InfectionsChina
-
University Hospital, Strasbourg, FranceRecruiting
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdRecruitingRespiratory Syncytial Virus InfectionsChina
-
GlaxoSmithKlineRecruiting
-
ShionogiRecruitingRespiratory Syncytial Virus InfectionsUnited States, Bulgaria, South Africa, Poland, Japan
-
Kevin WinthropAN2 Therapeutics, IncRecruitingMycobacterium Abscessus InfectionUnited States
-
First Affiliated Hospital of Ningbo UniversityRecruiting
-
Dilla UniversityNot yet recruiting
-
Emergent BioSolutionsDepartment of Health and Human Services; Centers for Disease Control and PreventionNot yet recruitingInfections, Bacterial
-
PfizerNot yet recruitingRespiratory Syncytial Virus Infections
Clinical Trials on Endotoxin, Lipopolysaccharide, LPS
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior
-
John SundyTerminated
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior
-
Radboud University Medical CenterCompletedInnate Immune ResponseNetherlands
-
Radboud University Medical CenterCompletedSepsis | Endotoxemia | Systemic Inflammation | ImmunosuppresionNetherlands
-
Radboud University Medical CenterExponential Biotherapies Inc.Completed
-
Karolinska InstitutetDanderyd HospitalCompleted
-
Radboud University Medical CenterUMC UtrechtCompletedSepsis, Endotoxemia, ImmunosuppressionNetherlands
-
National Jewish HealthNot yet recruitingAsthma | Asthma; EosinophilicUnited States
-
Robert J Noveck, M.D.Foundation for the National Institutes of HealthCompleted